Mucocutaneous Candidiasis
📧 Sign up to get email alerts when something new happens for Mucocutaneous Candidiasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Rituximab for Anti-cytokine Autoantibody-Associated Diseases [Phase 1]
Phase 1 trial evaluating Rituximab for anti-cytokine autoantibody-associated diseases, including Pulmonary Alveolar Proteinosis and Severe M…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
This clinical trial update notes ongoing recruitment for a natural history study of individuals with immune system defects that predispose t…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment [Phase 3]
Phase 3 study assessing ibrexafungerp in patients with invasive and mucocutaneous fungal diseases refractory to or intolerant of standard tr…
-
CLINICAL_TRIALS trial_result · 2024-06-07Clinical Trial Update: CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis [Phase 2]
Phase 2 clinical trial evaluating MAT2203 (CAMB) for chronic mucocutaneous candidiasis has completed and posted results as of 2024-06-07.
-
FDA approval · 2021-01-14FDA Approved: NYSTATIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an Original Application for NyStatin (nystatin) by Macleods Pharmaceuticals Limited, establishing a generic antifungal product.…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-05-30FDA Approved: NYSTATIN — Original Application (Leading Pharma, LLC)
FDA approved Leading Pharma, LLC's Original Application (ANDA208838) to market a generic nystatin product (Nystatin). This represents the fi…